AiCure’s revenue soars as it bolsters client list and executive team

New York, N.Y. – AiCure, a behavioral data analytics company targeting the healthcare and life sciences industries, today announced its revenue growth more than doubled year-over-year from 2017. This growth comes from a significant client increase – having added eight leading biotechnology and pharmaceutical clients to its roster over the past year. In addition, AiCure added four industry veterans to its management and board of directors teams. With these milestones, AiCure will continue to deliver on its commitment to improve health by understanding the science behind the human response to illness and treatment.

“The application of AI is starting to make its mark in healthcare, and the industry is beginning to see its unlimited potential,” said Adam Hanina, co-founder and CEO of AiCure. “At AiCure, we’re committed to improving patients’ health worldwide by leveraging innovative AI-enabled technology that sees, hears and understands behavior. With our strong customer partnerships and experienced executive leadership team, we are one step closer to achieving that goal and continuing our momentum into 2019.”

Business Growth

Over the past year, AiCure increased its revenue growth by 120 percent and bookings by 150 percent, as well as expanded its client list by more than 30 percent from 2017. Now, the company works with six of the top 10 pharmaceutical companies and 11 of the top 30 pharmaceutical companies globally.

Personnel Growth

Along with expanding its client portfolio, AiCure grew its workforce by 189 percent and built upon its existing executive team’s industry-leading expertise with the following additions:

  • Edward Ikeguchi, M.D., joined as Chief Medical Officer. Dr. Ikeguchi was previously a co-founder and Chief Medical Officer at Medidata for nearly a decade, where he helped grow the company from inception to its IPO in 2009.
  • Jindra Zitek, joined as Chief Operating Officer. Zitek has over 20 years of experience in operational strategy and was formerly with McKinsey, TPG and CIO of Chobani.
  • Isaac Galatzer-Levy, Ph.D., onboarded as Vice President of Clinical and Computational Neuroscience and Director of AiCure Labs. Dr. Galatzer-Levy’s background is in machine learning, neuroscience, and clinical psychology. Dr. Galatzer-Levy has lead large teams of researchers, received NIH, DOD, and foundation funding, published in over 75+ peer-reviewed publications, and has contributed significantly to the emerging field of digital mental health.
  • Gary Velasquez, CEO of Cogitativo, joined the company’s board of directors. Velasquez has more than 30 years of executive management experience in healthcare services and driving shareholder value.

About AiCure

AiCure is a behavioral data analytics company targeting the life sciences and healthcare industry to improve health by understanding the science behind the human response to illness and treatment. AiCure uses proprietary AI to capture and analyze visual and audio data from patients around their actions and responses to medical conditions and treatment across clinical trials and patient care. Clinically proven to enhance the effectiveness of medication, ensure patient compliance and improve health outcomes, AiCure’s platform provides pharmaceutical companies, healthcare providers, payers and government entities with novel insights around the science of patient behavior, allowing them to measure and modify it for better care. Founded in 2010 and funded by the National Institutes of Health (NIH), AiCure has more than 100 patents and works with large pharmaceutical companies to emerging biotechs worldwide.  Learn more about AiCure at

Around the web

The Department of Defense is gifting Case Western researchers a grant to study the use of AI in determining whether patients require surgery. 

This study brings light to the prospect of a "fully automated solution" for echocardiogram analysis, experts reported.

Experts noted a "significant" reduction in false positives and false negatives using their modified machine learning model.